DEVELOPMENT OF A NOVEL SELECTIVE PDE4 INHIBITOR FOR THE TREATMENT OF MULTIPLE SCLEROSIS

$246,443FY2024Defense Health AgencyDOD

Fannin Partners Llc

Investigators

View source on USAspending →